Medicines Healthcare Products Regulatory Agency
Wockhardt UK Ltd
Levothyroxine 100micrograms/5ml Oral Solution PL 29831/0495
|Batch Number||Expiry Date||Pack Size||First Distributed|
|I53481||31/03/2020||1 x 100ml||15/04/2019|
|I54522||31/05/2021||1 x 100ml||03/10/2019|
Active Pharmaceutical Ingredient: levothyroxine sodium
Brief description of the problem
Wockhardt UK Ltd is recalling specific batches of the above products from pharmacies and wholesalers as a precautionary measure due to notification of the impurity liothyronine exceeding the specification limit. Liothyronine is a degradant of Levothyroxine and can be used to treat the same conditions but with a faster onset and considered to be more potent than levothyroxine. This potency difference will result in different pharmacodynamic effects for patients.
Advice for healthcare professionals
Stop supplying the above products immediately. Quarantine all remaining stock and return it to your original supplier using your suppliers approved process.
Liothyronine is a breakdown product that is present in Levothyroxine formulations. Liothyronine, the synthetic form of the natural thyroid hormone tri-iodothyronine, can itself be used to treat an underactive thyroid but is generally reserved to treat more severe forms of the condition. This is because liothyronine has a faster onset of action and is also more potent than levothyroxine. These differences in action mean there is a higher risk of adverse effects with increasing liothyronine content and is why this is controlled within strict limits within levothyroxine preparations.
Company contacts for further information
For medical Information enquiries, please contact Medical Information on 01978 661261 or email@example.com.For enquiries relating to stock returns please contact Wockhardt UK Ltd Customer Services on 01978661261 or email firstname.lastname@example.org.
Levothyroxine 100micrograms/5ml Oral Solution - PL 29831/0495 - PIP code: 123-0051
Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.
NHS Regional teams are asked to forward this to relevant clinics, general practitioners and communitypharmacists.